Royce & Associates’s Aravive ARAV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
– Sell
-6,599
Closed -$438K – 1112
2016
Q2
$438K Hold
6,599
– – ﹤0.01% 1001
2016
Q1
$318K Sell
6,599
-2,166
-25% -$115K ﹤0.01% 1022
2015
Q4
$652K Sell
8,765
-1,667
-16% -$112K ﹤0.01% 988
2015
Q3
$722K Buy
+10,432
New +$979K ﹤0.01% 1004
2014
Q3
– Sell
-17
Closed -$3K – 1436
2014
Q2
$3K Buy
+17
New +$2.93K ﹤0.01% 1421

Other funds holding ARAV

Royce & Associates's ARAV Position: Q3 2016 in Review

Royce & Associates sold out of Aravive (ARAV) in Q3 2016, closing a stake of 6,599 shares — an estimated $438K sold.

Royce & Associates first reported a position in ARAV in Q2 2014 and held it in 5 quarters. The position peaked at $722K in Q3 2015. 74 funds tracked by Wall St. Rank hold ARAV as of Q3 2016.

  • Royce & Associates reported no remaining Aravive position as of Q3 2016 after selling out during the quarter.
  • Royce & Associates sold 6,599 Aravive shares in Q3 2016, an estimated $438K.
  • Royce & Associates first reported a position in Aravive in Q2 2014 and held it in 5 quarters.
  • Royce & Associates's Aravive position peaked at $722K in Q3 2015.
  • 74 funds tracked by Wall St. Rank held Aravive as of Q3 2016.

Based on Royce & Associates's 13F filing for Q3 2016, filed 14 Nov 2016.